Get the Stockscreener App
1.79
7.25%
-0.14
After Hours:
1.83
0.04
+2.23%
Century Therapeutics Inc stock is traded at $1.79, with a volume of 741.95K.
It is down -7.25% in the last 24 hours and down -7.73% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$1.93
Open:
$1.94
24h Volume:
741.95K
Relative Volume:
0.43
Market Cap:
$156.46M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.7817
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+0.00%
1M Performance:
-7.73%
6M Performance:
+265.60%
1Y Performance:
+144.97%
1-Day Range:
$1.79
$2.00
1-Week Range:
$1.65
$2.045
52-Week Range:
$0.3418
$2.71
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
1.79 | 168.69M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Expands By 320.2% - MarketBeat
Bull Run: Will Century Therapeutics Inc stock go up in YEARShort Setup & Target Return Focused Stock Picks - baoquankhu1.vn
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race - Seeking Alpha
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $3.80 Average PT from Brokerages - Defense World
Century Therapeutics (IPSC) Price Target Increased by 10.75% to 4.20 - Nasdaq
Valuation Update: Is Oramed Pharmaceuticals Inc stock overvalued or fairly pricedMarket Growth Review & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Is Century Therapeutics Inc stock undervalued right nowSell Signal & Technical Confirmation Alerts - baoquankhu1.vn
Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission - Finviz
Risk Analysis: Will Century Therapeutics Inc benefit from current market trendsDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
Piper Sandler highlights Century Therapeutics (IPSC) cash runway through 2029, upcoming IND submission - MSN
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Grows By 148.0% - MarketBeat
Why retail investors favor Century Therapeutics Inc. stockWeekly Trading Summary & High Accuracy Swing Entry Alerts - mfd.ru
Volume Report: Whats the RSI of Century Therapeutics Inc stock2025 Buyback Activity & Risk Managed Trade Strategies - baoquankhu1.vn
Century Therapeutics (IPSC) upgraded to strong buy: Here's what you should know - MSN
Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Century Therapeutics Regains Nasdaq Compliance, Halts Reverse Split - TipRanks
How sensitive is Century Therapeutics Inc to inflationQuarterly Portfolio Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Deep Track Capital, LP's Strategic Acquisition of Century Therap - GuruFocus
Century Therapeutics stock price target raised to $4 from $2 at Piper Sandler - Investing.com India
Will Century Therapeutics Inc. stock deliver long term returnsTrend Reversal & Reliable Price Action Trade Plans - bollywoodhelpline.com
Big Money Moves: Will Century Therapeutics Inc benefit from seasonalityJuly 2025 Trends & Weekly Breakout Watchlists - baoquankhu1.vn
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Rises By 32.1% - MarketBeat
Short Squeeze: Whats the RSI of Century Therapeutics Inc stockVolume Spike & Real-Time Buy Signal Alerts - baoquankhu1.vn
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $3.40 - Defense World
Century Therapeutics, Inc Updates on Pipeline and Clinical Progress - TradingView — Track All Markets
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Century Therapeutics (NASDAQ:IPSC) Upgraded at Zacks Research - Defense World
Century Therapeutics: Is This Stem Cell Stock Taking Root In 2026? - RTTNews
Is Century Therapeutics Inc. stock supported by strong cash flowsWeekly Trading Summary & Free Technical Pattern Based Buy Signals - Улправда
Can Century Therapeutics Inc. stock outperform in 2025 bull marketMarket Performance Summary & Expert Verified Stock Movement Alerts - ulpravda.ru
Century Therapeutics Inc. (IPSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How strong is Century Therapeutics Inc. stock revenue growthOil Prices & Stepwise Swing Trade Plans - ulpravda.ru
Can Century Therapeutics Inc. stock surprise with earnings upsidePortfolio Return Summary & AI Forecasted Stock Moves - Улправда
Century Therapeutics Inc.: Is an Upswing Approaching? - StocksToTrade
Century Therapeutics wins $135M private placement (IPSC:NASDAQ) - Seeking Alpha
Will Century Therapeutics Inc. stock deliver better than expected guidanceEarnings Growth Summary & Trade Opportunity Analysis Reports - Улправда
Can Century Therapeutics Inc. stock reach $100 price target2025 Geopolitical Influence & Safe Swing Trade Setups - ulpravda.ru
Century Therapeutics stock price target lowered to $6.60 at Clear Street - Investing.com Canada
Is Century Therapeutics Inc. stock attractive after correctionJuly 2025 PreEarnings & Consistent Growth Stock Picks - Улправда
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aug Swings: What sentiment indicators say about Century Therapeutics Inc. stockTrend Reversal & Daily Chart Pattern Signals - Улправда
Why Century Therapeutics Inc. stock is rated strong buyTrade Entry Report & Weekly Market Pulse Updates - Улправда
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes - Investing News Network
Century Therapeutics: New Leadership Sparks Interest - timothysykes.com
Layoff Watch: Is Century Therapeutics Inc. stock attractive for income investors2025 Risk Factors & Verified Short-Term Plans - ulpravda.ru
Century Therapeutics secures $135 million in private placement By Investing.com - Investing.com India
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cowan Chad | Chief Scientific Officer |
Dec 22 '25 |
Buy |
0.85 |
58,060 |
49,252 |
1,045,087 |
| Pfeiffenberger Brent | President and CEO |
Dec 12 '25 |
Buy |
0.58 |
52,000 |
30,352 |
3,322,990 |
| Carr Douglas | SVP Finance & Operations |
Dec 08 '25 |
Sale |
0.53 |
257 |
137 |
404,874 |
| Russotti Gregory | See Remarks |
Dec 08 '25 |
Sale |
0.53 |
526 |
280 |
390,982 |
2.09%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):